These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25433305)

  • 1. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treat cancers by targeting survivin: just a dream or future reality?
    Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
    Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting survivin in cancer: the cell-signalling perspective.
    Kanwar JR; Kamalapuram SK; Kanwar RK
    Drug Discov Today; 2011 Jun; 16(11-12):485-94. PubMed ID: 21511051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy.
    Wang S; Xu Y; Chan HF; Kim HW; Wang Y; Leong KW; Chen M
    J Control Release; 2016 Oct; 240():454-464. PubMed ID: 27091696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of apoptosis: clinical implications in cancer.
    Mohamed MS; Bishr MK; Almutairi FM; Ali AG
    Apoptosis; 2017 Dec; 22(12):1487-1509. PubMed ID: 29067538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
    Rödel F; Sprenger T; Kaina B; Liersch T; Rödel C; Fulda S; Hehlgans S
    Curr Med Chem; 2012; 19(22):3679-88. PubMed ID: 22680927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin as a Potential Target for Cancer Therapy.
    Soleimanpour E; Babaei E
    Asian Pac J Cancer Prev; 2015; 16(15):6187-91. PubMed ID: 26434815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: targeting death receptors and smac mimetics.
    Fulda S
    Clin Cancer Res; 2014 Aug; 20(15):3915-20. PubMed ID: 24824309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MKK3 as oncotarget.
    Bossi G
    Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
    [No Abstract]   [Full Text] [Related]  

  • 11. Survivin: A molecular biomarker in cancer.
    Jaiswal PK; Goel A; Mittal RD
    Indian J Med Res; 2015 Apr; 141(4):389-97. PubMed ID: 26112839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin--prognostic tumor biomarker in human neoplasms--review.
    Waligórska-Stachura J; Jankowska A; Waśko R; Liebert W; Biczysko M; Czarnywojtek A; Baszko-Błaszyk D; Shimek V; Ruchała M
    Ginekol Pol; 2012 Jul; 83(7):537-40. PubMed ID: 22880480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology based platforms for survivin targeted drug discovery.
    Samarasinghe RM; Gibbons J; Kanwar RK; Kanwar JR
    Expert Opin Drug Discov; 2012 Nov; 7(11):1083-92. PubMed ID: 22950742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting inhibitor of apoptosis proteins for therapeutic intervention.
    Ndubaku C; Cohen F; Varfolomeev E; Vucic D
    Future Med Chem; 2009 Nov; 1(8):1509-25. PubMed ID: 21426063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is survivin the potential Achilles' heel of cancer?
    Lladser A; Sanhueza C; Kiessling R; Quest AF
    Adv Cancer Res; 2011; 111():1-37. PubMed ID: 21704829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
    Italiano A
    Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting survivin for therapeutic discovery: past, present, and future promises.
    Peery RC; Liu JY; Zhang JT
    Drug Discov Today; 2017 Oct; 22(10):1466-1477. PubMed ID: 28577912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors.
    Zhang Z; Liao H; Chen X; Zheng Y; Liu Y; Tao X; Gu C; Dong L; Duan T; Yang Y; Liu X; Yu Y; Feng Y
    Eur J Obstet Gynecol Reprod Biol; 2011 Mar; 155(1):69-74. PubMed ID: 21074309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin as a preferential target for cancer therapy.
    Mobahat M; Narendran A; Riabowol K
    Int J Mol Sci; 2014 Feb; 15(2):2494-516. PubMed ID: 24531137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.